4D Molecular Therapeutics (NASDAQ:FDMT) Insider Scott Bizily Sells 1,635 Shares of Stock

Key Points

• Insider selling: Scott Bizily sold 1,635 FDMT shares at an average of $12.20, reducing his direct stake by 15.95% to 8,617 shares. He also sold 1,635 shares on August 13 and 9,810 shares in June.
• Stock performance: 4D Molecular Therapeutics shares rose 19.4% to $14.55, near their 52-week high of $15.03, on trading volume well above average.
• Financials and outlook: The company missed quarterly EPS estimates ($1.04 loss versus $1.02 expected) but exceeded revenue estimates with $3.78 million. Analysts maintain a “Moderate Buy” consensus with an average price target of $29.62.

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) insider Scott Bizily sold 1,635 shares of the business's stock in a transaction on Monday, August 17th. The shares were sold at an average price of $12.20, for a total transaction of $19,947.00. Following the completion of the transaction, the insider directly owned 8,617 shares of the company's stock, valued at $105,127.40. This trade represents a 15.95% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Scott Bizily also recently made the following trade(s):

• On Thursday, August 13th, Scott Bizily sold 1,635 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $12.00, for a total value of $19,620.00.
• On Tuesday, June 23rd, Scott Bizily sold 9,810 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $12.00, for a total value of $117,720.00.

4D Molecular Therapeutics Trading Up 19.4%

NASDAQ:FDMT traded up $2.36 on Monday, reaching $14.55. The company's stock had a trading volume of 3,444,983 shares, compared to its average volume of 805,311. 4D Molecular Therapeutics, Inc. has a 1-year low of $5.97 and a 1-year high of $15.03. The business's 50-day moving average price is $10.94 and its two-hundred day moving average price is $9.89. The firm has a market cap of $760.67 million, a PE ratio of -5.53 and a beta of 2.73. The company has a debt-to-equity ratio of 0.05, a quick ratio of 8.03 and a current ratio of 8.03.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last released its quarterly earnings results on Thursday, August 13th. The company reported ($1.04) EPS for the quarter, missing analysts' consensus estimates of ($1.02) by ($0.02). 4D Molecular Therapeutics had a negative return on equity of 41.33% and a negative net margin of 194.74%.The business had revenue of $3.78 million for the quarter, compared to analyst estimates of $3.62 million. Equities research analysts anticipate that 4D Molecular Therapeutics, Inc. will post -3.88 earnings per share for the current fiscal year.

Hedge Funds Weigh In On 4D Molecular Therapeutics

Several hedge funds have recently made changes to their positions in FDMT. Sei Investments Co. raised its stake in 4D Molecular Therapeutics by 8.9% in the first quarter. Sei Investments Co. now owns 12,862 shares of the company's stock valued at $120,000 after buying an additional 1,050 shares during the period. Martingale Asset Management L P boosted its stake in shares of 4D Molecular Therapeutics by 12.4% during the 4th quarter. Martingale Asset Management L P now owns 11,775 shares of the company's stock worth $88,000 after acquiring an additional 1,303 shares during the period. Dimensional Fund Advisors LP increased its holdings in shares of 4D Molecular Therapeutics by 3.7% during the 3rd quarter. Dimensional Fund Advisors LP now owns 58,006 shares of the company's stock worth $504,000 after acquiring an additional 2,069 shares during the last quarter. Russell Investments Group Ltd. raised its stake in 4D Molecular Therapeutics by 11.7% in the 2nd quarter. Russell Investments Group Ltd. now owns 21,816 shares of the company's stock valued at $81,000 after acquiring an additional 2,284 shares during the period. Finally, Prelude Capital Management LLC lifted its holdings in 4D Molecular Therapeutics by 11.1% during the 3rd quarter. Prelude Capital Management LLC now owns 23,000 shares of the company's stock valued at $200,000 after purchasing an additional 2,300 shares during the last quarter. 99.27% of the stock is owned by institutional investors.

Analyst Ratings Changes

FDMT has been the topic of a number of research reports. B. Riley Financial reaffirmed a "buy" rating on shares of 4D Molecular Therapeutics in a research note on Monday. The Goldman Sachs Group restated a "buy" rating and set a $32.00 price objective on shares of 4D Molecular Therapeutics in a report on Thursday. Chardan Capital raised shares of 4D Molecular Therapeutics to a "strong-buy" rating in a research report on Tuesday, July 28th. Wall Street Zen lowered shares of 4D Molecular Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, May 9th. Finally, HC Wainwright reiterated a "buy" rating and set a $36.00 target price on shares of 4D Molecular Therapeutics in a report on Monday, July 20th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $29.62.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D's pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source